DNDi identified an interesting new hit compound active against Leishmania donovani from an innovative screening collaboration with Pfizer. DNDi has subsequently prepared more than 700 novel compounds in VL series 12. These structures (see link to .sdf file below) form the basis for further optimisation by DNDi’s Lead Optimization consortium, with additional expert scientific support from Takeda Pharmaceutical Company Limited, and with generous financial support from the GHIT Fund. Further details of this project will be published in due course.